Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,914 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05577091RecruitingPhase 1
CAR-T cell therapy for recurrent glioblastoma
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
Beijing, Beijing MunicipalityAges 18–70 - NCT05578053Recruiting
Dalpiciclib for hormone receptor–positive advanced breast cancer
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Shijiazhuang, HebeiAges 18 years+ - NCT05582876Recruiting
PET/MR scan to plan personalized prostate cancer treatment
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
BialystokAges 18–99 - NCT05584826RecruitingPhase 2
MDMA therapy for cancer patients and their partner’s distress
This Phase 2 study tests whether MDMA-assisted therapy can reduce adjustment-related distress in cancer patients who are paired with a loved one who is also concerned. It may help the patient and their significant other cope better through structured therapy sessions, with safety checks before and after each session.
Rockville, MarylandAges 18 years+ - NCT05586360RecruitingPhase 2
Testing how a statin may change immune markers in prostate cancer
This Phase 2 study tests whether taking simvastatin can change “immune regulation” markers in men with intermediate- to high-risk localized prostate cancer. It also looks at whether this could help lower the risk of cancer coming back after planned prostate surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05597852Recruiting
Rectal gel spacer to help repeat prostate radiation
This trial studies whether placing a soft gel spacer near the rectum can make “salvage” prostate radiation safer and more tolerable when prostate cancer comes back locally. It may help reduce side effects by creating extra space between the rectum and the radiation area.
Toronto, OntarioAges 18 years+ - NCT05607329Recruiting
Surgery plus chemo versus chemo alone for ovarian cancer relapse
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hangzhou, ZhejiangAges 18–70 - NCT05629546RecruitingPhase 1
Nivolumab and relatlimab with lab-made memory NK cells
This Phase 1 study tests a new form of immune cells (NK cells) along with nivolumab and relatlimab for advanced melanoma that has worsened after prior PD-1/PD-L1 treatments. It may help your body recognize and attack melanoma cells more strongly.
St Louis, MissouriAges 18 years+ - NCT05630794RecruitingPhase 1
Test ONC201 to prevent colorectal polyp return in high-risk people
This Phase 1 study tests whether ONC201 is safe and may help prevent colorectal polyps (adenomas) from coming back. You’d also undergo planned colon/rectum camera exams to check for new or changing polyps.
Ann Arbor, MichiganAges 18 years+ - NCT05632809RecruitingPhase 2
Boosting immune cells after lung cancer chemoradiation
This trial studies whether a medicine called NKTR-255 can help restore and strengthen immune cells after standard chemoradiation for non-small cell lung cancer. The goal is to improve how well the body can fight the cancer after initial treatment.
Houston, TexasAges 18 years+ - NCT05641623RecruitingPhase 2
Study drug for depression that didn’t improve on common antidepressants
This Phase 2 trial tests OSU6162 added to an SSRI or SNRI in people whose major depression did not improve enough after trying specific antidepressants for at least 6 weeks. It may help reduce depression symptoms when standard treatments haven’t worked well.
Lund, Skåne CountyAges 25–65 - NCT05641935RecruitingPhase 2
Ultrasound scan to check kidney cancer return after ablation
This study tests whether a special ultrasound scan with contrast can help doctors find kidney cancer that comes back after a procedure called ablation. It may help improve monitoring by comparing the ultrasound results with CT or MRI scans done soon after treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05644457Recruiting
Testing early blood or tissue signals to track head and neck treatment
This study looks for early “biomarkers” (signals in blood or tissue) to see how well head and neck cancer treatments are working over time. It may help doctors adjust treatment sooner based on those early signals.
LondonAges 18 years+ - NCT05648136Recruiting
Blood test study for immune markers in miscarriage and IVF failure
This study looks at immune-related blood patterns and other measurements to better understand why some women have repeated pregnancy loss or repeated IVF implantation failure. If you qualify, your answers and test results may help researchers identify biomarkers that could guide future care.
Amiens, PicardieAges 18–39 - NCT05652374RecruitingPhase 4
Gag therapy for repeat bladder infections, compared to standard antibiotics
This trial tests a therapy (called GAG therapy) to prevent repeat urinary tract infections (UTIs) in adult women. It compares how similar the results are to a well-known antibiotic standard (nitrofurantoin) to see if it works reliably.
Nijmegen, GelderlandAges 18 years+ - NCT05654454RecruitingPhase 3
Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
ArkhangelskAges 18 years+ - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05658731Recruiting
Radiation planning study to protect thinking in children
This study compares how radiation is planned to see whether it better protects thinking and memory in children and young adults. It may help future patients by learning which planning approach leads to better cognitive (thinking) outcomes.
Washington D.C., District of ColumbiaAges 1–26 - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT05663710RecruitingPhase 1/Phase 2
Study of 177Lu antibody and medicines for first advanced kidney cancer
This trial tests a new combination of targeted medicines (including 177Lu girentuximab) plus immunotherapy to treat people with advanced clear cell kidney cancer who have not had prior systemic (whole-body) treatment. It aims to shrink tumors and control disease by attacking cancer in multiple ways.
Houston, TexasAges 18 years+ - NCT05672147RecruitingPhase 1
CD33 CAR T cells for hard-to-treat AML
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Duarte, CaliforniaAges 18 years+ - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Chicago, IllinoisAges 18 years+ - NCT05697926Recruiting
Personalized immune T-cell therapy study for head and neck cancer
This study focuses on testing a personalized immune therapy (made from your tumor-fighting T cells) for people with head and neck cancer. It may help patients whose cancer is new and untreated or whose cancer has come back or is not responding to standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,914 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.